AVXL
Price
$9.95
Change
-$0.17 (-1.68%)
Updated
Aug 15 closing price
Capitalization
854.21M
128 days until earnings call
LQDA
Price
$25.95
Change
-$0.14 (-0.54%)
Updated
Aug 15 closing price
Capitalization
2.23B
87 days until earnings call
Interact to see
Advertisement

AVXL vs LQDA

Header iconAVXL vs LQDA Comparison
Open Charts AVXL vs LQDABanner chart's image
Anavex Life Sciences
Price$9.95
Change-$0.17 (-1.68%)
Volume$950.54K
Capitalization854.21M
Liquidia
Price$25.95
Change-$0.14 (-0.54%)
Volume$2.84M
Capitalization2.23B
AVXL vs LQDA Comparison Chart in %
Loading...
AVXL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LQDA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AVXL vs. LQDA commentary
Aug 17, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AVXL is a Hold and LQDA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 17, 2025
Stock price -- (AVXL: $9.94 vs. LQDA: $25.95)
Brand notoriety: AVXL and LQDA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AVXL: 88% vs. LQDA: 101%
Market capitalization -- AVXL: $854.21M vs. LQDA: $2.23B
AVXL [@Biotechnology] is valued at $854.21M. LQDA’s [@Biotechnology] market capitalization is $2.23B. The market cap for tickers in the [@Biotechnology] industry ranges from $100.71B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AVXL’s FA Score shows that 0 FA rating(s) are green whileLQDA’s FA Score has 1 green FA rating(s).

  • AVXL’s FA Score: 0 green, 5 red.
  • LQDA’s FA Score: 1 green, 4 red.
According to our system of comparison, LQDA is a better buy in the long-term than AVXL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AVXL’s TA Score shows that 4 TA indicator(s) are bullish while LQDA’s TA Score has 5 bullish TA indicator(s).

  • AVXL’s TA Score: 4 bullish, 5 bearish.
  • LQDA’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, LQDA is a better buy in the short-term than AVXL.

Price Growth

AVXL (@Biotechnology) experienced а -10.24% price change this week, while LQDA (@Biotechnology) price change was +35.09% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.90%. For the same industry, the average monthly price growth was +26.70%, and the average quarterly price growth was +20.91%.

Reported Earning Dates

AVXL is expected to report earnings on Dec 22, 2025.

LQDA is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (+9.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
LQDA($2.23B) has a higher market cap than AVXL($854M). LQDA YTD gains are higher at: 120.663 vs. AVXL (-7.402). AVXL has higher annual earnings (EBITDA): -45.65M vs. LQDA (-122.53M). LQDA has more cash in the bank: 170M vs. AVXL (116M). AVXL has less debt than LQDA: AVXL (88.2K) vs LQDA (148M). LQDA has higher revenues than AVXL: LQDA (14.1M) vs AVXL (0).
AVXLLQDAAVXL / LQDA
Capitalization854M2.23B38%
EBITDA-45.65M-122.53M37%
Gain YTD-7.402120.663-6%
P/E RatioN/AN/A-
Revenue014.1M-
Total Cash116M170M68%
Total Debt88.2K148M0%
FUNDAMENTALS RATINGS
AVXL vs LQDA: Fundamental Ratings
AVXL
LQDA
OUTLOOK RATING
1..100
5327
VALUATION
overvalued / fair valued / undervalued
1..100
59
Fair valued
95
Overvalued
PROFIT vs RISK RATING
1..100
8115
SMR RATING
1..100
96100
PRICE GROWTH RATING
1..100
4535
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
9021

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AVXL's Valuation (59) in the Biotechnology industry is somewhat better than the same rating for LQDA (95) in the Pharmaceuticals Major industry. This means that AVXL’s stock grew somewhat faster than LQDA’s over the last 12 months.

LQDA's Profit vs Risk Rating (15) in the Pharmaceuticals Major industry is significantly better than the same rating for AVXL (81) in the Biotechnology industry. This means that LQDA’s stock grew significantly faster than AVXL’s over the last 12 months.

AVXL's SMR Rating (96) in the Biotechnology industry is in the same range as LQDA (100) in the Pharmaceuticals Major industry. This means that AVXL’s stock grew similarly to LQDA’s over the last 12 months.

LQDA's Price Growth Rating (35) in the Pharmaceuticals Major industry is in the same range as AVXL (45) in the Biotechnology industry. This means that LQDA’s stock grew similarly to AVXL’s over the last 12 months.

LQDA's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as AVXL (100) in the Biotechnology industry. This means that LQDA’s stock grew similarly to AVXL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AVXLLQDA
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
81%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
89%
Bearish Trend 2 days ago
78%
Momentum
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
85%
MACD
ODDS (%)
Bearish Trend 2 days ago
82%
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 10 days ago
79%
Bullish Trend 3 days ago
85%
Declines
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 16 days ago
83%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 2 days ago
78%
Aroon
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
AVXL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LQDA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LMGTX62.97N/A
N/A
ClearBridge International Growth C
JCVSX25.11N/A
N/A
JHancock Classic Value R2
EFCNX22.71N/A
N/A
Emerald Insights Investor
SREZX13.45N/A
N/A
PGIM Select Real Estate Z
MXVHX7.10N/A
N/A
Empower Large Cap Value Instl

AVXL and

Correlation & Price change

A.I.dvisor indicates that over the last year, AVXL has been loosely correlated with PLRX. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if AVXL jumps, then PLRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AVXL
1D Price
Change %
AVXL100%
-1.63%
PLRX - AVXL
48%
Loosely correlated
-1.59%
TENX - AVXL
47%
Loosely correlated
+0.34%
RXRX - AVXL
46%
Loosely correlated
+2.30%
AXON - AVXL
45%
Loosely correlated
+0.59%
MNMD - AVXL
41%
Loosely correlated
-1.13%
More

LQDA and

Correlation & Price change

A.I.dvisor tells us that LQDA and AXON have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that LQDA and AXON's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LQDA
1D Price
Change %
LQDA100%
-0.54%
AXON - LQDA
32%
Poorly correlated
+0.59%
AVXL - LQDA
30%
Poorly correlated
-1.63%
KURA - LQDA
29%
Poorly correlated
+11.21%
DMAC - LQDA
28%
Poorly correlated
+0.33%
WHWK - LQDA
28%
Poorly correlated
-1.23%
More